Global Biosimilars Market 2026-2030

Description

The global biosimilars market is forecasted to grow by USD 38171.7 mn during 2025-2030, accelerating at a CAGR of 13.3% during the forecast period. The report on the global biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing patent expirations and intensifying focus on cost-effectiveness, rising global incidence of chronic and autoimmune diseases, technological advancements in progress in biomanufacturing.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2026
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	12.1%
CAGR	13.3%
Incremental Value	$38171.7 mn

Technavio's global biosimilars market is segmented as below:

By Product Type

Monoclonal antibodies
Insulin
Human growth hormone
Others

By Application

Oncology and hematology
Endocrinology
Immunology
Nephrology

By Manufacturing Type

In-house manufacturing
Contract manufacturing

Geography

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the strategic shift towards interchangeability and pursuit of bio betters as one of the prime reasons driving the global biosimilars market growth during the next few years. Also, expansion into novel therapeutic areas and increased focus on emerging markets and embracing vertical integration and advanced manufacturing technologies will lead to sizable demand in the market.

The report on the global biosimilars market covers the following areas:

Global biosimilars market sizing
Global biosimilars market forecast
Global biosimilars market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global biosimilars market vendors that include Abbott Laboratories, Biocon Ltd., Dr. Reddys Laboratories Ltd., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kashiv Biosciences LLC, Mabxience Holding S.L., NeuClone Pty Ltd., Organon and Co., Pfizer Inc., Reliance Life Sciences Pvt. Ltd., Samsung Bioepis Co. Ltd., Sandoz Group AG, STADA Arzneimittel AG, Teva Pharmaceutical Ltd., Viatris Inc., Zentiva Group, Zydus Lifesciences Ltd.. Also, the global biosimilars market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR70710

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Manufacturing Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Biosimilars Market 2020 - 2024
- Historic Market Size - Data Table on Global Biosimilars Market 2020 - 2024 ($ million)
5.2 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
5.4 Manufacturing Type segment analysis 2020 - 2024
- Historic Market Size - Manufacturing Type Segment 2020 - 2024 ($ million)
5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 AI Impact on Global Biosimilars Market
6.2 Impact of Geopolitical Conflict on Global Biosimilars Market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Product Type

8.1 Market segments
8.2 Comparison by Product Type
8.3 Monoclonal antibodies - Market size and forecast 2025-2030
8.4 Insulin - Market size and forecast 2025-2030
8.5 Human growth hormone - Market size and forecast 2025-2030
8.6 Others - Market size and forecast 2025-2030
8.7 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)

9 Market Segmentation by Application

9.1 Market segments
9.2 Comparison by Application
9.3 Oncology and hematology - Market size and forecast 2025-2030
9.4 Endocrinology - Market size and forecast 2025-2030
9.5 Immunology - Market size and forecast 2025-2030
9.6 Nephrology - Market size and forecast 2025-2030
9.7 Market opportunity by Application
- Market opportunity by Application ($ million)

10 Market Segmentation by Manufacturing Type

10.1 Market segments
10.2 Comparison by Manufacturing Type
10.3 In-house manufacturing - Market size and forecast 2025-2030
10.4 Contract manufacturing - Market size and forecast 2025-2030
10.5 Market opportunity by Manufacturing Type
- Market opportunity by Manufacturing Type ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation
12.2 Geographic comparison
12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Thailand - Market size and forecast 2025-2030
- 12.5.6 Indonesia - Market size and forecast 2025-2030
12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 South Africa - Market size and forecast 2025-2030
- 12.6.7 Colombia - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

13.1 Market drivers
- Increasing patent expirations and intensifying focus on cost-effectiveness
- Rising global incidence of chronic and autoimmune diseases
- Technological advancements in progress in biomanufacturing
13.2 Market challenges
- Navigating evolving and complex regulatory frameworks
- Intensive patent litigation and strategic obstacles
- Overcoming physician and patient reluctance
13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
13.4 Market opportunities
- Strategic shift towards interchangeability and pursuit of bio betters
- Expansion into novel therapeutic areas and increased focus on emerging markets
- Embracing vertical integration and advanced manufacturing technologies

14 Competitive Landscape

14.1 Overview
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
- Overview on factors of disruption
14.4 Industry risks
- Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled
- Companies covered
15.2 Company ranking index
- Company ranking index
15.3 Market positioning of companies
- Matrix on companies position and classification
15.4 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- SWOT
15.5 Biocon Ltd.
- Biocon Ltd. - Overview
- Biocon Ltd. - Business segments
- Biocon Ltd. - Key offerings
- Biocon Ltd. - Segment focus
- SWOT
15.6 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
15.7 Fresenius Kabi AG
- Fresenius Kabi AG - Overview
- Fresenius Kabi AG - Product / Service
- Fresenius Kabi AG - Key offerings
- SWOT
15.8 Intas Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd. - Overview
- Intas Pharmaceuticals Ltd. - Product / Service
- Intas Pharmaceuticals Ltd. - Key offerings
- SWOT
15.9 NeuClone Pty Ltd.
- NeuClone Pty Ltd. - Overview
- NeuClone Pty Ltd. - Product / Service
- NeuClone Pty Ltd. - Key offerings
- SWOT
15.10 Organon and Co.
- Organon and Co. - Overview
- Organon and Co. - Product / Service
- Organon and Co. - Key offerings
- SWOT
15.11 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
15.12 Reliance Life Sciences Pvt. Ltd.
- Reliance Life Sciences Pvt. Ltd. - Overview
- Reliance Life Sciences Pvt. Ltd. - Product / Service
- Reliance Life Sciences Pvt. Ltd. - Key offerings
- SWOT
15.13 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Business segments
- Sandoz Group AG - Key news
- Sandoz Group AG - Key offerings
- Sandoz Group AG - Segment focus
- SWOT
15.14 STADA Arzneimittel AG
- STADA Arzneimittel AG - Overview
- STADA Arzneimittel AG - Business segments
- STADA Arzneimittel AG - Key offerings
- STADA Arzneimittel AG - Segment focus
- SWOT
15.15 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
15.16 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
15.17 Zentiva Group
- Zentiva Group - Overview
- Zentiva Group - Product / Service
- Zentiva Group - Key offerings
- SWOT
15.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT

16 Appendix

16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
16.3 Currency conversion rates for US$
- Currency conversion rates for US$
16.4 Research methodology
- Research methodology
16.5 Data procurement
- Information sources
16.6 Data validation
- Data validation
16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
16.8 Data synthesis
- Data synthesis
16.9 360 degree market analysis
- 360 degree market analysis
16.10 List of abbreviations
- List of abbreviations